This is an early but highly promising proof-of-concept for in vivo CAR-T, a novel modality that could disrupt the cell therapy landscape. Monitor for Phase 2 dose selection and expansion data; the lack of lymphodepletion and favorable safety profile differentiate LB2501 from current CAR-T therapies. Near-term catalyst: next clinical update or regulatory interaction.
Price Chart
Executive Summary
Legend Biotech presented first-in-human proof-of-concept data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, at EHA 2026. At the higher dose level (DL2), 6/6 patients achieved objective responses and 5/6 achieved complete responses with no serious adverse events or deaths, supporting a potential paradigm shift in cell therapy delivery.
Key Facts
- LB2501 achieved 100% ORR (6/6) and 83.3% CR rate (5/6) at dose level 2 in R/R B-NHL patients
- No dose-limiting toxicities, serious adverse events, ICANS, or deaths reported across 12 patients
- In vivo CAR-T generation without lymphodepletion — potential to simplify treatment and expand access
- Data presented in late-breaking session at EHA 2026 Congress (Abstract #LB5006)
- All responses at DL2 were ongoing at data cutoff; CAR-T cells detectable up to 116 days
Financial Impact
Early-stage proof-of-concept; no revenue or deal value disclosed. LB2501 is investigational with no approved status.
Risk Factors
- Phase 1 data in only 12 patients — small sample size limits generalizability
- In vivo CAR-T is unproven at scale; manufacturing and durability unknowns remain
- Competition from other in vivo CAR-T programs (e.g., Umoja, Sana) and approved ex vivo CAR-Ts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311435 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 15, 2026 12d ago | 6-K | $19.80 | awaiting T+20 | — | $21.56 (+8.89%) |
Oct 13, 2026 14d ago | 6-K | $17.88 | awaiting T+20 | — | $21.56 (+20.58%) |
Sep 29, 2026 28d ago | 144 | $18.82 $21.16 | ▲ +12.41% | ▲ +11.75% | $21.56 (+14.56%) |
Sep 25, 2026 4w ago | 6-K | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.56 (+12.82%) |
Sep 25, 2026 4w ago | Press Release | $19.11 $19.27 | ▲ +0.84% | ▲ +2.31% | $21.56 (+12.82%) |
Sep 15, 2026 6w ago | 6-K | $17.67 $17.88 | ▲ +1.19% | ▼ −1.53% | $21.56 (+22.01%) |
Sep 14, 2026 6w ago | 6-K | $18.53 $17.80 | ▼ −3.94% | ▼ −6.20% | $21.56 (+16.35%) |
Aug 11, 2026 11w ago | 6-K | $21.83 $19.91 | ▼ −8.80% | ▼ −7.74% | $21.56 (−1.24%) |
Jul 27, 2026 13w ago | 6-K | $19.27 $20.94 | ▼ −8.67% | ▼ −5.37% | $21.56 (−11.88%) |
Jul 27, 2026 13w ago | Press Release | $19.27 $20.94 | ▲ +8.67% | ▲ +5.37% | $21.56 (+11.88%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers